SCHEMBL5651233

SCHEMBL5651233

CCN(CC)CCCNC(=O)c1ccc(-c2nc3ccc(OC)cc3[nH]2)c(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.54
HDAC6 Q9UBN7 2/20 0.50
PRMT5 O14744 1/20 0.50
WDR77 Q9BQA1 1/20 0.50
F9 P00740 1/20 0.47
TMEM97 Q5BJF2 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
APLNR P35414 2/20 0.45
GAA P10253 2/20 0.45
CHEK2 O96017 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GLA P06280 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649495 0.94 FLT3 (0.52) FLT3HDAC6PRMT5WDR77F9
SCHEMBL5651251 0.93 PRMT5 (0.50) FLT3HDAC6PRMT5WDR77TMEM97
SCHEMBL5653023 0.90 PRMT5 (0.50) HDAC6PRMT5WDR77TMEM97SIGMAR1
SCHEMBL5653988 0.88 FLT3 (0.51) FLT3HDAC6PRMT5WDR77F9
SCHEMBL5650247 0.88 PRSS12 (0.50) HDAC6PRMT5WDR77TMEM97SIGMAR1
SCHEMBL5651430 0.87 FLT3 (0.69) FLT3HDAC6F9CHEK2CHEK1
SCHEMBL5649510 0.87 FLT3 (0.46) FLT3HDAC6PRMT5WDR77TMEM97
SCHEMBL5650220 0.85 PRMT5 (0.48) FLT3HDAC6PRMT5WDR77TMEM97
SCHEMBL5650229 0.85 PRMT5 (0.48) HDAC6PRMT5WDR77TMEM97SIGMAR1
SCHEMBL5653849 0.85 PRMT5 (0.47) FLT3HDAC6PRMT5WDR77TMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 FLT3 1968/4885HDAC6 537/4885PRMT5 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.